ライフサイエンスコーパス: filariasis

1 n in a chronic helminth infection (lymphatic filariasis).

2 North Americans with no history of lymphatic filariasis.

3 ecology and pathogenesis of human lymphatic filariasis.

4 (H2(d)), the only fully permissive model of filariasis.

5 seases such as river blindness and lymphatic filariasis.

6 n of programs aimed at eliminating lymphatic filariasis.

7 symbionts into the blood after treatment for filariasis.

8 malayi, a causative agent of human lymphatic filariasis.

9 or nonantigenemic individuals with clinical filariasis.

10 ofile are well-established features of human filariasis.

11 gamma- and IL-4-producing cells in lymphatic filariasis.

12 infection and morbidity rates in bancroftian filariasis.

13 e of the causative agents of human lymphatic filariasis.

14 sociated with cytokine patterns in lymphatic filariasis.

15 rugia malayi, a causative agent of lymphatic filariasis.

16 ntial to accelerate elimination of lymphatic filariasis.

17 diseases like river blindness and lymphatic filariasis.

18 i, one of the nematodes that cause lymphatic filariasis.

19 nia africana, which are vectors of lymphatic filariasis.

20 as well as of nematodes that cause lymphatic filariasis.

21 mosquitoes that transmit West Nile fever and filariasis.

22 erlying T cell immune tolerance in lymphatic filariasis.

23 fic T-cell response seen in patent lymphatic filariasis.

24 he vector-borne parasitic disease, lymphatic filariasis.

25 account for the T cell hyporesponsiveness in filariasis.

26 erlying the dysfunctional immune response in filariasis.

27 concept of protective immunity in lymphatic filariasis, 19 adult residents of a Wuchereria bancrofti

28 oncepts of disease progression (asymptomatic filariasis = 25%; clinical filariasis with active infect

29 with a low baseline prevalence of lymphatic filariasis (5%), the triple-drug regimen reduced the num

30 ases including river blindness and lymphatic filariasis affect hundreds of millions of people annuall

31 asymptomatic microfilaremic or with clinical filariasis and active infection).

32 associated with disease in chronic lymphatic filariasis and could potentially have an important role

33 ore effective than DEC + ALB for Bancroftian filariasis and has the potential to accelerate eliminati

34 Lymphatic filariasis and intestinal helminth infections are import

35 Lymphatic filariasis and loiasis are major human diseases caused b

36 nets are being widely used in areas in which filariasis and malaria are coendemic.

37 d by filarial nematodes, including lymphatic filariasis and onchocerciasis (river blindness) has tran

38 Lymphatic filariasis and onchocerciasis are parasitic helminth dis

39 Lymphatic filariasis and onchocerciasis are parasitic helminth dis

40 ger-scale ivermectin treatment for lymphatic filariasis and onchocerciasis in areas where L. loa infe

41 cycline treatment regimens against lymphatic filariasis and onchocerciasis.

42 in the global effort to eliminate lymphatic filariasis and possibly for the control of other mosquit

43 enya, where BCG is administered at birth and filariasis and schistosomiasis are endemic, were examine

44 administration for elimination of lymphatic filariasis and soil-transmitted helminth infections in R

45 ticle reviews available diagnostic tests for filariasis and their potential use as tools for differen

46 to reduce microfilariae in blood (lymphatic filariasis) and skin (onchocerciasis).

47 of Kenya where schistosomiasis, bancroftian filariasis, and geohelminth infections are endemic.

48 tic agents against onchocerciasis, lymphatic filariasis, and heartworm.

49 h as guinea worm, schistosomiasis, lymphatic filariasis, and onchocerciasis, suggests that many of th

50 panosomiasis, Chagas disease, leishmaniasis, filariasis, and schistosomiasis.

51 lymphoedema, and elephantiasis in lymphatic filariasis, and skin disease and blindness in onchocerci

52 an area highly endemic for schistosomiasis, filariasis, and tuberculosis in Kenya would either fail

53 within-host population dynamics of lymphatic filariasis, and use a simulated goodness-of-fit (GOF) me

54 d Th1 responses observed in patent lymphatic filariasis are associated with decreased expression of T

55 Global efforts to eliminate lymphatic filariasis are based on the annual mass administration o

56 mpaigns against onchocerciasis and lymphatic filariasis being conducted in areas where Onchocerca vol

57 ential for school-based control of lymphatic filariasis by investigating the efficacy and tolerabilit

58 th ivermectin plus albendazole for lymphatic filariasis cannot be applied in central Africa, because

59 Brugian filariasis (caused by the nematodes Brugia malayi and B.

60 te detection is essential for the success of filariasis control programs.

61 ity, validating it as a potential target for filariasis control.

62 ver, few such programmes exist for lymphatic filariasis, despite evidence that single-dose treatment

63 s, whether with subclinical or with clinical filariasis, distinct and limited T cell populations are

64 idence that protective immunity to lymphatic filariasis does occur and that it is probably T cell-med

65 rial antigens affects the natural history of filariasis during childhood.

66 Lymphatic filariasis (elephantiasis) is a global public health pro

67 immunocompromised mouse models suggest that filariasis elicits a complex host immune response involv

68 Improved diagnostic tests are needed for filariasis elimination programs (to identify areas of en

69 tential use as tools for different phases of filariasis elimination programs.

70 in A is an antibiotic to develop further for filariasis elimination without concern for cross-resista

71 es, including dengue, malaria, and lymphatic filariasis, exact a devastating toll on global health an

72 nvestigated in Malian villages coendemic for filariasis (Fil) and malaria.

73 Lymphatic filariasis, frequently caused from Wuchereria bancrofti

74 ting Global Programme to Eliminate Lymphatic Filariasis (GPELF) is largely based on a strategy of mas

75 The Global Program to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000 with the princip

76 l Programme for the Elimination of Lymphatic Filariasis (GPELF), as interaction dynamics may change w

77 the Global Programme to Eliminate Lymphatic Filariasis (GPELF).

78 e elimination of onchocerciasis or lymphatic filariasis has been delayed in Central Africa because of

79 l to accelerate the elimination of lymphatic filariasis if high population coverage of mass drug admi

80 l to accelerate the elimination of lymphatic filariasis if high population coverage of mass drug admi

81 for control of onchocerciasis and lymphatic filariasis in Africa.

82 ration of albendazole to eliminate lymphatic filariasis in areas where loiasis is co-endemic and iver

83 en for accelerating elimination of lymphatic filariasis in different epidemiological settings.

84 We give case examples including filariasis in eastern Burma and vector-borne diseases (C

85 ns is the cause of the second most prevalent filariasis in Gabon, but so far reports on the presence

86 cellular parasites responsible for lymphatic filariasis in humans--and the APC with which they come i

87 Onchocerciasis and lymphatic filariasis in particular are the cause of much disfigure

88 is a severe asthmatic syndrome of lymphatic filariasis, in which an allergic response is induced to

89 Drugs to treat filariasis include diethylcarbamazine, ivermectin, and a

90 r knowledge of the host-seeking behaviour of filariasis infected mosquitoes is lacking.

91 to be qualitatively different from those of filariasis-infected subjects; whereas filarial antigens

92 To determine whether maternal filariasis influences the risk of infection by and immun

93 and the effectiveness of currently proposed filariasis intervention options.

94 Lymphatic filariasis is a disease characterized by immune dysregul

95 Bancroftian filariasis is a major public health problem in Papua New

96 ent global initiative to eliminate lymphatic filariasis is a major renewed commitment to reduce or el

97 Lymphatic filariasis is a tropical disease caused by the nematode

98 Patent lymphatic filariasis is characterized by a profound down-regulatio

99 Patent lymphatic filariasis is characterized by antigen-specific T-cell u

100 Patent lymphatic filariasis is characterized by profound Ag-specific T ce

101 Humans living in areas where filariasis is endemic vary greatly in their exposure to

102 On an island in which bancroftian filariasis is endemic, 29 microfilaremic and 16 "endemic

103 ss-sectional study in an area of Kenya where filariasis is endemic.

104 n living on a Pacific island where lymphatic filariasis is endemic.

105 ic T-cell unresponsiveness seen in lymphatic filariasis is mediated, in part, by diminished antigen-p

106 d from individuals from North America, where filariasis is not endemic, were also positive for anti-W

107 ma development in individuals with lymphatic filariasis is presently poorly understood.

108 ctra of clinical manifestations of lymphatic filariasis is still unknown.

109 Elimination of onchocerciasis and lymphatic filariasis is targeted for 2020.

110 Lymphatic filariasis is targeted for elimination as a public healt

111 One of the causative agents of lympahtic filariasis is the nematode parasite Brugia malayi that r

112 Lymphatic filariasis (LF) and onchocerciasis are priority neglecte

113 Available treatments for lymphatic filariasis (LF) are limited in their longterm clearance

114 chieving the global elimination of lymphatic filariasis (LF) by 2020.

115 Malaria and lymphatic filariasis (LF) continue to cause a considerable public

116 possible strategy for eliminating lymphatic filariasis (LF) in post-conflict countries such as the D

117 Lymphatic filariasis (LF) is a major cause of acute and chronic mo

118 The familial recurrence risk of lymphatic filariasis (LF) is unknown.

119 tropical diseases (NTD), including lymphatic filariasis (LF), scaled up dramatically after the signin

120 ommunities tasked with eliminating lymphatic filariasis (LF), the underlying cause of elephantiasis a

121 Using rodent models of lymphatic filariasis (Litomosoides sigmodontis) and noncerebral ma

122 In a laboratory model of filariasis, Litomosoides sigmodontis infection of suscep

123 ls with clinical manifestations of lymphatic filariasis may be currently infected or not.

124 ce with Wuchereria bancrofti due to maternal filariasis may influence susceptibility to infection.

125 Lymphatic filariasis occurs in endemic pockets.

126 or the diagnostic evaluation of persons with filariasis of unclear etiology.

127 the data available for five NTDs (lymphatic filariasis, onchocerciasis, intestinal helminthiasis, sc

128 amples from patients with loiasis, lymphatic filariasis, onchocerciasis, mansonellosis, or other helm

129 oadministration of drugs to target lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transm

130 from filarial nematodes that cause lymphatic filariasis or onchocerciasis, resulting in blocked worm

131 - to 10-year-old children of mothers without filariasis or schistosomiasis produced 10-fold more IFN-

132 duals, antigenemic individuals with clinical filariasis, or nonantigenemic individuals with clinical

133 the nonantigenemic individuals with clinical filariasis (P = 0.02).

134 the nonantigenemic individuals with clinical filariasis (P = 0.04).

135 or less, were overrepresented in any single filariasis patient.

136 est this hypothesis in bancroftian lymphatic filariasis, pedigree data were collected twice during an

137 Elimination of filariasis requires a macrofilaricide treatment that can

138 ever and yellow fever viruses, and lymphatic filariasis, respectively.

139 rugia malayi, a causative agent of lymphatic filariasis, resulting in the identification of more than

140 Focussing on lymphatic filariasis, schistosomiasis and soil-transmitted helmint

141 Parasitic infections such as filariasis, schistosomiasis, and amoebiasis can be assoc

142 s, could be administered as short courses to filariasis target populations with potential to reduce a

143 the nonantigenemic individuals with clinical filariasis than in the asymptomatic microfilaremic indiv

144 and Th2 immune responses occurs in lymphatic filariasis that is governed at the transcriptional level

145 h the putatively immune state in bancroftian filariasis (that is, both microfilaria and antigen free)

146 site products has been investigated in human filariasis to understand immune hyporesponsiveness.

147 Mathematical models of filariasis transmission can serve as an effective tool f

148 nitor populations for possible resurgence of filariasis transmission following suspension of MDA.

149 study of diseases as diverse as lymphedema, filariasis, transplant rejection, obesity, and tumor met

150 Thus, in Mf(-) mice, filariasis upset a delicate immunological balance in mal

151 Culex pipiens mosquito group (including the filariasis vector C. quinquefasciatus) a very unusual de

152 ite of disease activity in human bancroftian filariasis, we have compared the repertoire of TCR Vbeta

153 ls and antigenemic individuals with clinical filariasis were grouped together to constitute all activ

154 toes introduce the pathogens responsible for filariasis, West Nile virus, St.

155 Human lymphatic filariasis, which afflicts an estimated 120 million peop

156 , tuberculosis, leishmaniasis, and lymphatic filariasis, which impose tremendous public health burden

157 ion (asymptomatic filariasis = 25%; clinical filariasis with active infection = 60%; clinical filaria

158 ymptomatic microfilaremic or having clinical filariasis with active infection or without current acti

159 rasites has provided a new approach to treat filariasis with antibiotics.

160 e and well-tolerated treatment for lymphatic filariasis with significant activity against adult worms

161 malayi, a causative agent of human lymphatic filariasis, with PBMC of normal individuals.

162 riasis with active infection = 60%; clinical filariasis without active infection = 71%).

163 ma were seen only in the group with clinical filariasis without active infection.

164 ne treatment on the major cause of lymphatic filariasis, Wuchereria bancrofti.